Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15558962 | 1.00 | CYP2D6 (0.41) | CYP2D6CYP2C19GABRR1DPP7 | |
| SCHEMBL18063332 | 0.88 | CYP2D6 (0.39) | CYP2D6CYP2C19GABRR1DPP7 | |
| SCHEMBL18342325 | 0.83 | CYP2D6 (0.44) | CYP2D6CYP2C19GABRR1 | |
| SCHEMBL18063354 | 0.83 | CYP2D6 (0.44) | CYP2D6CYP2C19GABRR1 | |
| SCHEMBL14844643 | 0.83 | CYP2D6 (0.44) | CYP2D6CYP2C19GABRR1 | |
| SCHEMBL18261537 | 0.81 | CYP2D6 (0.43) | CYP2D6CYP2C19 | |
| SCHEMBL15558877 | 0.78 | CYP2D6 (0.40) | CYP2D6CYP2C19 | |
| SCHEMBL8970424 | 0.77 | GABRR1 (0.41) | GABRR1DPP7 | |
| SCHEMBL14844611 | 0.76 | CYP2D6 (0.46) | CYP2D6CYP2C19 | |
| SCHEMBL3544030 | 0.76 | CYP2D6 (0.46) | CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10556854-B2 | Bacterial efflux pump inhibitors | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-02-11 | — | — | US | disclosed |
| US-20190084919-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2019-03-21 | — | — | US | disclosed |
| WO-2017147333-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2017-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10556854-B2 | Bacterial efflux pump inhibitors | ABCB11, ABCB1, SLC47A1 | CYP2D6 235/4885CYP2C19 395/4885GABRR1 2460/4885 |
| US-20190084919-A1 | BACTERIAL EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, SLC47A1 | CYP2D6 235/4885CYP2C19 395/4885GABRR1 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.